Including PRO data is crucial to capture symptom and treatment impact directly from leukemia patients. Explore the methodology to
While oncology remains the remains the most widely researched therapeutic area, clinical trials are complex and have consistently shown some of the lowest productivity rates over the last 10 years. Of many factors, the longer trial duration compared to other therapeutic areas, the significant number of patients and sites, the multiplicity of eligibility criteria, and the ever-increasing number of endpoints contribute particularly to the significant complexity of oncology clinical trials.
“Oncology clinical trials are particularly complex for patients and sites suffering from long study duration. Patient compliance can be affected by adverse events & perception of study burden over time, while protocols may be amended with additional visits, inclusion/exclusion criteria modification, or additional safety procedures.“
Dr. Frédéric Fiteni, oncology expert, Kayentis scientific advisory board.
At Kayentis, we have the necessary oncology experience to mitigate the specific challenges of complex oncology clinical trials. We support the development of your eCOA strategy to define relevant endpoints and focus on those that matter most to patients, allowing your research to improve both the health and quality of life of cancer patients.
As one of the biggest research area, oncology remains the focus of the clinical trials pipeline, comprising 44% of
Cultural differences and individual preferences have a significant impact on healthcare and clinical trial experience. Solutions exist in attempt
Kayentis Europe
19 bis, chemin du vieux Chêne
38240 Meylan
France
Phone: +33 (0)4 76 00 54 20
Kayentis US
186 South Street
Suite 600
Boston, Massachusetts 02111
USA
